Bio-ADM as a Biomarker of Refilling in Chronic Hemodialysis Patient
NCT ID: NCT05339009
Last Updated: 2022-04-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
150 participants
OBSERVATIONAL
2022-04-01
2023-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Evaluating the Pronostic Value of Vascular Refilling Rate on Mortality in Chronic Kidney Disease Patients on Dialysis
NCT04810338
Inflammation and Nutritional Parameters in Hemodialysis Patients Using Reprocessed Dialyzers
NCT00440908
Functionality of Albumin in the Context of Hemodialysis
NCT06561191
Redox State in the Course of Chronic Renal Insufficiency and Hemodialysis: Implications in Morbimortality
NCT00684034
Continuous Registration of Bioimpedance During Hemodialysis
NCT03990818
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
All patients receive conventional dialysis treatment at inclusion
All patients receive conventional dialysis treatment at inclusion
BioADM determination in plasma
BioADM determination in plasma
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BioADM determination in plasma
BioADM determination in plasma
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Anuric patient
Exclusion Criteria
* Patient under guardianship ou curatorship
* Patient deprived of liberty
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Montpellier
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jean-Paul CRISTOL, MD PhD
Role: PRINCIPAL_INVESTIGATOR
University Hospital Center of Montpellier, FRANCE
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UH Montpellier
Montpellier, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RECHMPL21_0068
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.